Antisoma Sells Oral Fludarabine to Sanofi-aventis
Taskin Ahmed
Abstract
Antisoma sold the US rights to oral fludarabine (Oforta™) to Sanofi-aventis. The deal brings an immediate cash payment of US$60 M to Antisoma and further payments totalling US$5 M.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.